Jump to content

BIIB131

From Wikipedia, the free encyclopedia
(Redirected from SMTP-7)
BIIB131
Names
IUPAC name
(2S)-2,5-bis[(2S,3S)-2-[(3E)-4,8-dimethylnona-3,7-dienyl]-3,5-dihydroxy-2-methyl-7-oxo-4,9-dihydro-3H-pyrano[2,3-e]isoindol-8-yl]pentanoic acid
Other names
    • SMTP-7
    • TMS-007
Identifiers
3D model (JSmol)
  • InChI=1S/C51H68N2O10/c1-30(2)14-9-16-32(5)18-11-21-50(7)43(56)26-36-41(54)24-34-38(45(36)62-50)28-52(47(34)58)23-13-20-40(49(60)61)53-29-39-35(48(53)59)25-42(55)37-27-44(57)51(8,63-46(37)39)22-12-19-33(6)17-10-15-31(3)4/h14-15,18-19,24-25,40,43-44,54-57H,9-13,16-17,20-23,26-29H2,1-8H3,(H,60,61)/b32-18+,33-19+/t40-,43-,44-,50-,51-/m0/s1
    Key: CRNDCHORWGDFGR-PXTWCNKMSA-N
  • CC(=CCC/C(=C/CC[C@]1([C@H](CC2=C(C=C3C(=C2O1)CN(C3=O)CCC[C@@H](C(=O)O)N4CC5=C6C(=C(C=C5C4=O)O)C[C@@H]([C@](O6)(C)CC/C=C(\C)/CCC=C(C)C)O)O)O)C)/C)C
Properties
C51H68N2O10
Molar mass 869.109 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).

BIIB131 (also known as SMTP-7 or TMS-007) is a prothrombolytic small-molecule drug developed by Biogen for acute ischemic stroke.[1][2][3]

References

[edit]
  1. ^ Yuan, Long; Jiang, Di; Pinkham, Andrew; Kirkland, Melissa (November 2023). "Development, validation and application of a capillary microsampling LC–MS/MS method for the quantification of BIIB131 (SMTP-7) in rat plasma". Journal of Pharmaceutical and Biomedical Analysis. 236: 115752. doi:10.1016/j.jpba.2023.115752. PMID 37769527.
  2. ^ Kostrubsky, Vick; Liu, Ying; Muste, Cathy; Gu, Chungang; Kirkland, Melissa; Nishimura, Naoko; Hasegawa, Keiko; Hasumi, Keiji; Yuan, Long (December 2023). "Preclinical safety, toxicokinetics and metabolism of BIIB131, a novel prothrombolytic agent for acute stroke". Regulatory Toxicology and Pharmacology. 145: 105498. doi:10.1016/j.yrtph.2023.105498. PMID 37778433. S2CID 263297651.
  3. ^ Wang, Bo; Lin, Yiqing (2022). "Absolute configuration determination of SMTP-7 via microcrystal electron diffraction (MicroED)". Chemical Communications. 58 (94): 13071–13074. doi:10.1039/D2CC05218K. PMID 36305866. S2CID 253184088.